Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Details
This study is being done to know if we extend the time without extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer (an immunotherapy drug called atezolizumab). As well to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for extensive stage small cell lung cancer.
Eligibility
You can join if...
Inclusion Criteria
Pathologically proven diagnosis of extensive stage small cell lung cancer
Patients with bone metastases are eligible
For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to registration
Exclusion Criteria
-Metastatic disease invading the liver (>3 metastases), heart or >10 metastatic sites detectable after induction systemic therapy
-Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 5 years prior to randomization
-History of autoimmune disease
-Severe, active co-morbidity
-Pregnancy or women who are breastfeeding and unwilling to discontinue.
-History of allogeneic organ transplant.
-Patients who have had immunotherapy-induced pneumonitis.